Document Detail

The role of dietary long-chain n-3 fatty acids in anti-cancer immune defense and R3230AC mammary tumor growth in rats: influence of diet fat composition.
MedLine Citation:
PMID:  12088117     Owner:  NLM     Status:  MEDLINE    
We determined if long-chain n-3 fatty acids fed as part of a: (1) high polyunsaturated fat diet (currently recommended by several health agencies) or (2) low polyunsaturated fat diet (representative of that consumed by a large segment of the North American population) improved antitumor immune defense and inhibited tumor growth. Rats were fed one of four semi-purified diets (20% w/w fat) for 21 days pre- and 17 days post- R3230AC mammary tumor implantation. The polyunsaturated to saturated fatty acid (P/S) ratio was either 1 (high P/S diet) or 0.35 (low P/S diet). At each P/S ratio, diets provided long-chain n-3 fatty acids at 0 or 5% w/w of total fat. Long-chain n-3 fatty acids fed in a high P/S diet did not affect tumor growth or host immune responses. In contrast, feeding long-chain n-3 fatty acids in a low P/S diet increased natural killer cell cytotoxicity, splenocyte nitric oxide and interleukin-2 production, and the proportion of activated (CD25+) CD8+ and CD28+ cells, but did not significantly inhibit tumor growth. For both P/S diets, tumor cells from rats fed long-chain n-3 fatty acids had a higher n-3 content and n-3/n-6 ratio in phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol. Furthermore, the magnitude of increase in n-3 fatty acid incorporation into tumor phospholipids was greater when fed in a low P/S diet. We demonstrated that the dietary P/S ratio significantly influences the effect of long-chain n-3 fatty acids on host immune responses and n-3 fatty acid incorporation into tumor cells. These findings warrant further consideration when designing dietary recommendations.
Lindsay E Robinson; M Thomas Clandinin; Catherine J Field
Related Documents :
20875947 - A restricted cubic spline approach to assess the association between high fat fish inta...
19549757 - Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and...
14669967 - Interactive effects of dietary palm oil concentration and water temperature on lipid di...
8827697 - The ratio of n-6 to n-3 polyunsaturated fatty acids in the rat diet alters serum lipid ...
10457607 - Numerous huge iron particles appeared around micro blood vessels under intestinal epith...
1951147 - Meal size and frequency: effect on the thermic effect of food.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  73     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-06-28     Completed Date:  2003-01-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  145-60     Citation Subset:  IM    
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / diet therapy,  immunology*,  prevention & control*
Cytokines / biosynthesis
Dietary Fats / administration & dosage*,  immunology*
Fatty Acids / administration & dosage
Fatty Acids, Omega-3 / administration & dosage*,  immunology
Fatty Acids, Unsaturated / administration & dosage
Fluorescent Antibody Technique, Indirect
Killer Cells, Natural / drug effects
Neoplasm Transplantation
Nitric Oxide / biosynthesis
Random Allocation
Rats, Inbred F344
Spleen / cytology,  metabolism
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Cytokines; 0/Dietary Fats; 0/Fatty Acids; 0/Fatty Acids, Omega-3; 0/Fatty Acids, Unsaturated; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Next Document:  Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-...